SCHEMBL846331

SCHEMBL846331

CC=Cc1ccc(C(=O)OC)cn1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.59
KDM4E B2RXH2 3/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
ALDH1A1 P00352 3/20 0.46
CA1 P00915 3/20 0.44
CA2 P00918 3/20 0.44
CA12 O43570 2/20 0.44
CA7 P43166 2/20 0.44
CA9 Q16790 2/20 0.44
CA14 Q9ULX7 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
RAB9A P51151 2/20 0.43
NPC1 O15118 1/20 0.43
KMT2A Q03164 1/20 0.43
MAPT P10636 3/20 0.43
ALOX15 P16050 2/20 0.43
HTT P42858 1/20 0.43
TSHR P16473 1/20 0.41
XDH P47989 1/20 0.41
PTPN1 P18031 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL846330 1.00 MAPK1 (0.59) MAPK1KDM4EL3MBTL1ALDH1A1CA1
SCHEMBL30372051 0.84 MAPK1 (0.61) MAPK1KDM4EL3MBTL1ALDH1A1CA1
SCHEMBL655582 0.84 MAPK1 (0.61) MAPK1KDM4EL3MBTL1ALDH1A1CA1
SCHEMBL9000473 0.83 MAPK1 (0.56) MAPK1KDM4EL3MBTL1ALDH1A1CA1
SCHEMBL7389658 0.83 KDM4E (0.57) MAPK1KDM4EL3MBTL1ALDH1A1CA1
SCHEMBL15894494 0.83 MAPK1 (0.56) MAPK1KDM4EL3MBTL1ALDH1A1CA1
SCHEMBL7389657 0.83 KDM4E (0.57) MAPK1KDM4EL3MBTL1ALDH1A1CA1
SCHEMBL31601570 0.83 MAPK1 (0.59) MAPK1KDM4EL3MBTL1ALDH1A1CA1
SCHEMBL846377 0.83 MAPK1 (0.59) MAPK1KDM4EL3MBTL1ALDH1A1CA1
SCHEMBL18940416 0.82 MAPK1 (0.54) MAPK1KDM4EL3MBTL1ALDH1A1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200247798-A1 THERAPEUTIC AGENT FOR ANXIETY DISORDERS KYOWA KIRIN CO LTD (JP) 2020-08-06 US disclosed
US-10407440-B2 Therapeutic agent for motor disorders KYOWA HAKKO KIRIN CO., LTD. (JP) 2019-09-10 US disclosed
EP-3378860-A1 THERAPEUTIC AGENT FOR MOTOR DISORDERS Kyowa Hakko Kirin Co., Ltd. (JP) 2018-09-26 EP disclosed
EP-2433938-B1 THERAPEUTIC AGENT FOR MOTOR DISORDERS KYOWA HAKKO KIRIN CO LTD (JP) 2018-04-18 EP disclosed
US-20170275296-A1 THERAPEUTIC AGENT FOR MOTOR DISORDERS KYOWA KIRIN CO., LTD. (JP) 2017-09-28 US disclosed
US-9714257-B2 Therapeutic agent for motor disorders KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-07-25 US disclosed
EP-2474544-B1 THERAPEUTIC AGENT FOR ANXIETY DISORDERS KYOWA HAKKO KIRIN CO LTD (JP) 2017-07-12 EP disclosed
EP-2474543-B1 THERAPEUTIC AGENT FOR MOOD DISORDERS KYOWA HAKKO KIRIN CO LTD (JP) 2017-05-03 EP disclosed
US-9249135-B2 Therapeutic agent for mood disorders KYOWA HAKKO KIRIN CO., LTD. (JP) 2016-02-02 US disclosed
US-20150225417-A1 THERAPEUTIC AGENT FOR MOTOR DISORDERS KYOWA KIRIN CO., LTD. (JP) 2015-08-13 US disclosed
US-20150080415-A1 THERAPEUTIC AGENT FOR ANXIETY DISORDERS KYOWA KIRIN CO., LTD. (JP) 2015-03-19 US disclosed
US-20120184554-A1 THERAPEUTIC AGENT FOR MOOD DISORDERS KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-07-19 US disclosed
EP-2474543-A1 THERAPEUTIC AGENT FOR MOOD DISORDERS Kyowa Hakko Kirin Co., Ltd. (JP) 2012-07-11 EP disclosed
EP-2474544-A1 THERAPEUTIC AGENT FOR ANXIETY DISORDERS Kyowa Hakko Kirin Co., Ltd. (JP) 2012-07-11 EP disclosed
US-20120172362-A1 THERAPEUTIC AGENT FOR ANXIETY DISORDERS KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-07-05 US disclosed
US-20120101101-A1 THERAPEUTIC AGENT FOR MOTOR DISORDERS KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-04-26 US disclosed
EP-2433938-A1 THERAPEUTIC AGENT FOR MOTOR DISORDERS Kyowa Hakko Kirin Co., Ltd. (JP) 2012-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184554-A1 THERAPEUTIC AGENT FOR MOOD DISORDERS TPH1, HDAC1, HDAC2 MAPK1 787/4885KDM4E 2195/4885L3MBTL1 2006/4885
US-10407440-B2 Therapeutic agent for motor disorders DDT, COMT, SLC6A3 MAPK1 747/4885KDM4E 4721/4885L3MBTL1 699/4885
US-20170275296-A1 THERAPEUTIC AGENT FOR MOTOR DISORDERS DDT, COMT, SLC6A3 MAPK1 747/4885KDM4E 4721/4885L3MBTL1 699/4885
US-20120172362-A1 THERAPEUTIC AGENT FOR ANXIETY DISORDERS TAAR1, SLC6A1, GABBR1 MAPK1 691/4885KDM4E 3799/4885L3MBTL1 1461/4885
US-20120101101-A1 THERAPEUTIC AGENT FOR MOTOR DISORDERS DDT, COMT, SLC6A3 MAPK1 747/4885KDM4E 4721/4885L3MBTL1 699/4885
US-20200247798-A1 THERAPEUTIC AGENT FOR ANXIETY DISORDERS TAAR1, SLC6A1, GABBR1 MAPK1 691/4885KDM4E 3799/4885L3MBTL1 1461/4885
US-20150080415-A1 THERAPEUTIC AGENT FOR ANXIETY DISORDERS TAAR1, SLC6A1, GABBR1 MAPK1 691/4885KDM4E 3799/4885L3MBTL1 1461/4885
US-20150225417-A1 THERAPEUTIC AGENT FOR MOTOR DISORDERS DDT, COMT, SLC6A3 MAPK1 747/4885KDM4E 4721/4885L3MBTL1 699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.